Drug Trial Radar · NCT06087835
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,835
Actual
Start
Nov 7, 2023
Primary completion
Feb 18, 2027
Study completion Feb 18, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
Conditions
- Chronic Kidney Disease With High Proteinuria
Interventions
Zibotentan/DapagliflozinDrug
Participants will receive zibotentan/dapagliflozin in fixed-dose combination as per the arms they are randomized to
DapagliflozinDrug
Participants will receive dapagliflozin as per the arms they are randomized to
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in eGFR from baselineTime frame: At month 24
Locations
296 sites in 30 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama
Research Site
Sun City West, Arizona
Research Site
Bakersfield, California
Research Site
Huntington Park, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Northridge, California
Research Site
Oxnard, California
Research Site
San Carlos, California
Research Site
San Dimas, California
Research Site
Tarzana, California
Research Site
Victorville, California
Research Site
Arvada, Colorado
Research Site
Denver, Colorado
Research Site
Boynton Beach, Florida
Research Site
Hialeah, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Jensen Beach, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Fayetteville, Georgia
Research Site
Champaign, Illinois
Research Site
Chicago, Illinois
Research Site
Hinsdale, Illinois
Research Site
Island Lake, Illinois
Research Site
Skokie, Illinois
Research Site
Bowling Green, Kentucky
Research Site
Shreveport, Louisiana
Research Site
Silver Spring, Maryland
Research Site
Flint, Michigan
Research Site
Flint, Michigan
Research Site
Troy, Michigan
Research Site
City of Saint Peters, Missouri
Research Site
Albany, New York
Research Site
Middletown, New York
Research Site
Orchard Park, New York
Research Site
Greenville, North Carolina
Research Site
Jacksonville, North Carolina
Showing 40 of 296 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.